R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
This partnership has led to a 10% boost in delivery speed
Subscribe To Our Newsletter & Stay Updated
